Cargando…

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer

Central nervous system (CNS) metastasis is one of the serious complications of epidermal growth factor receptor (EGFR)‐mutant lung cancer, which arises due to poor penetration of the brain–blood barrier by EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs). Although osimertinib, a third‐generation EGFR‐TKI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dong Ha, Choi, Yun Jung, Sung, Ki Jung, Yoo, Seon‐A, Sung, Young Hoon, Kim, Jeong Kon, Choi, Chang‐Min, Yun, Miyong, Lee, Eun Yong, Jin, Yong Suk, Cook, Seungho, Rho, Jin Kyung, Lee, Jae Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275278/ https://www.ncbi.nlm.nih.gov/pubmed/30350450 http://dx.doi.org/10.1002/1878-0261.12394

Ejemplares similares

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Jung, Sangyong, et al.
Publicado: (2021)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2019)

Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines
por: Ji, Wonjun, et al.
Publicado: (2020)

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
por: Lee, Youngjoo, et al.
Publicado: (2017)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation
por: Kim, Jung Soo, et al.
Publicado: (2017)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
por: Yoon, Hee-Young, et al.
Publicado: (2020)

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
por: Choi, Se Hoon, et al.
Publicado: (2017)

Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer
por: Na, Im II, et al.
Publicado: (2007)

Modification Effect of PARP4 and ERCC1 Gene Polymorphisms on the Relationship between Particulate Matter Exposure and Fasting Glucose Level
por: Kim, Jin Hee, et al.
Publicado: (2022)

Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through β-catenin-Mediated Epithelial-Mesenchymal Transition
por: Yun, Miyong, et al.
Publicado: (2020)

Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
por: Yoon, Hyo‐Jin, et al.
Publicado: (2021)

Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
por: Yoon, Hyo‐Jin, et al.
Publicado: (2021)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Park, Ji Hyun, et al.
Publicado: (2016)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

Spontaneous Dissecting Aneurysm of the Intracranial Vertebral Artery: Management Strategies
por: Lee, Jae Whan, et al.
Publicado: (2007)

Intracranial Meningioma-induced Parkinsonism
por: Kim, Ji-In, et al.
Publicado: (2014)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway
por: Yun, Un-Jung, et al.
Publicado: (2017)

Metals in Particulate Pollutants Affect Peak Expiratory Flow of Schoolchildren
por: Hong, Yun-Chul, et al.
Publicado: (2007)

Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma
por: Yun, Miyong, et al.
Publicado: (2018)

Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses
por: Lee, Seungho, et al.
Publicado: (2017)

Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report
por: Choi, Seong Ji, et al.
Publicado: (2016)

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2022)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

Maternal Exposure to Particulate Matter during Pregnancy and Adverse Birth Outcomes in the Republic of Korea
por: Kim, Yu Jin, et al.
Publicado: (2019)

A Case of Cicatricial Alopecia Associated with Erlotinib
por: Yang, Bo Hee, et al.
Publicado: (2011)

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer
por: Bae, Gab-Yong, et al.
Publicado: (2013)

Oleanolic Acid Protects the Skin from Particulate Matter-Induced Aging
por: Kim, Youn Jin, et al.
Publicado: (2021)

Recurrence of Small Cerebral Aneurysms (< 4 mm) Treated Endovascularly Using Target® Nano™ Coils
por: Kim, Sung Min, et al.
Publicado: (2018)

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
por: Hyun, Dong-gon, et al.
Publicado: (2020)

Influence of nano-structured alumina coating on shear bond strength between Y-TZP ceramic and various dual-cured resin cements
por: Lee, Jung-Jin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h46qipkottvvdbgo2o9i4drlbh